Indaptus Therapeutics, Inc.INDPNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank74
5Y CAGR-86.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-86.6%/yr
Long-term compound
Percentile
P74
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 23.98% |
| Q2 2025 | 20.39% |
| Q1 2025 | -48.63% |
| Q4 2024 | -35.13% |
| Q3 2024 | -1.42% |
| Q2 2024 | 37.05% |
| Q1 2024 | -51.29% |
| Q4 2023 | 30.32% |
| Q3 2023 | -77.26% |
| Q2 2023 | 57.54% |
| Q1 2023 | -124.44% |
| Q4 2022 | 51.95% |
| Q3 2022 | -46.17% |
| Q2 2022 | -0.98% |
| Q1 2022 | 11.92% |
| Q4 2021 | 37.13% |
| Q3 2021 | -334.88% |
| Q2 2021 | -56.83% |
| Q1 2021 | 13.73% |
| Q4 2020 | -121.51% |
| Q3 2020 | 544967.21% |
| Q2 2020 | -97.85% |
| Q1 2020 | 99.99% |
| Q4 2019 | 21.36% |
| Q3 2019 | 37.69% |
| Q2 2019 | -45.74% |
| Q1 2019 | 5.18% |
| Q4 2018 | 28.67% |
| Q3 2018 | -15.69% |
| Q2 2018 | 9.50% |
| Q1 2018 | -42.99% |
| Q4 2017 | -11.50% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |
| Q4 2015 | -1537.86% |
| Q3 2015 | 84.62% |
| Q2 2015 | 0.00% |
| Q1 2015 | 0.00% |